Can we prolong life of patients with advanced chronic kidney disease: What is the clinical evidence?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 3, 2011, Pages 88-93

  Stompór, Tomasz ^a   Olszewski, Artur ^a   Kierzkowska, Irena ^a  

^a UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Anemia; Chronic kidney disease; Dyslipidemia; Hypertension; Mineral and bone disorders

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM PHOSPHATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TRIACYLGLYCEROL;

ANEMIA; BONE DISEASE; CHRONIC KIDNEY DISEASE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTERVENTION STUDY; LIFE SUSTAINING TREATMENT; RENAL REPLACEMENT THERAPY; REVIEW;

EID: 79954466254     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Agarwal S, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension. 2009; 53: 860-866.
2. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009; 373: 1009-1015.
3. Gross P, Schirutschke H, Barnett K. Should we prescribe blood pressure lowering drugs to every patient with advanced chronic kidney disease? A comment on two recent meta-analyses. Pol Arch Med Wewn. 2009; 119: 644-647.
4. Piecha G, Adamczak M, Ritz E. Dyslipidemia in chronic kidney disease: pathogenesis and intervention. Pol Arch Med Wewn. 2009; 119: 487-492.
5. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248. (Pubitemid 41058323)
6. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-1407.
7. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010; 160: 785-794.
8. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218. (Pubitemid 39031360)
9. Floege J. When man turns to stone: extraosseous calcification in uremic patients. Kidney Int. 2004; 65: 2447-2462. (Pubitemid 38670036)
10. Guerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000; 15: 1014-1021. (Pubitemid 30410374)
11. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-1525. (Pubitemid 38477776)
12. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005; 46: 58-67. (Pubitemid 40852012)
13. Curran MP, Robinson DM. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease. Drugs. 2009; 69: 2329-2349.
14. Chertow GM, Burke SK, Raggi P, et al.; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
15. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824. (Pubitemid 43169927)
16. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 113: S1-130.
17. Matuszkiewicz-Rowińska J. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of mineral and bone disorders in chronic kidney disease. Pol Arch Med Wewn. 2010; 120: 300-306.
18. Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007; 2: 898-905.
19. Tomczak-Watras W, Strożecki P, Zuchora Z, et al. Influence of the 6-month anemia therapy with erythropoietin on renal function and some hemodynamic parameters in predialysis patients. Pol Arch Med Wewn. 2009; 119: 45-52.
20. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol. 2001; 12: 2465-2473. (Pubitemid 33021125)
21. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999; 10: 1309-1316. (Pubitemid 29246997)
22. Delano BG. Improvements in quality of life following treatment with r-HuEpo in anemic hemodialysis patients. Am J Kidney Dis. 1989; 14: 478-485.
23. Massimetti C, Pontillo D, Feriozzi S, et al. Impact of human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif. 1998; 16: 317-324. (Pubitemid 29237629)
24. Besarab A, Bolton WK, Browne JK, et al. The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590. (Pubitemid 28385655)
25. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098. (Pubitemid 44749317)
26. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084. (Pubitemid 44749316)
27. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the anemia correction in diabetes (ACORD) study. Am J Kidney Dis. 2007; 49: 194-207. (Pubitemid 46178405)
28. Phrommintikul A, Haas SJ, Krum H. Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369: 381-388. (Pubitemid 46188479)
29. Pfeffer MA, Burdmann EA, Chen CY, et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032.
30. Eknoyan G, Beck GJ, Cheung AK, et al.; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347: 2010-2019. (Pubitemid 35461657)
31. Locatelli F, Martin-Malo A, Hannedouche T, et al.; Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009; 20: 645-654.
32. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002; 13: 1307-1320. (Pubitemid 34441412)
33. Wańkowicz Z. Peritoneal dialysis and its role in the demography and epidemiology of chronic kidney disease. Pol Arch Med Wewn. 2009; 119: 810-814.
34. van der Weerd NC, Penne EL, van der Dorpel MA, et al. Haemodiafiltration: promise for the future? Nephrol Dial Transplant. 2008; 23: 438-443.
35. Wesołowski P, Saracyn M, Nowak Z, Wańkowicz Z. Insulin resistance as a novel therapeutic target in patients with chronic kidney disease treated with dialysis. Pol Arch Med Wewn. 2010; 120: 54-57.
36. Onuigbo MC. Reno-prevention vs reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET - a call for more circumspection. QJM. 2009; 102: 155-167.